Physician profile
John M Johnson
NPI 1992881239
$6,416.51
in general payments reported to CMS, 2019-2025
25 companies · $827 in 2025
The $827 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $552 · 2021: $432 · 2022: $2,170 · 2023: $496 · 2024: $693 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,053.53 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $1,374.26 | 2019-2025 | Cequa |
| Allergan, INC. | $312.13 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $301.48 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $286.76 | 2019-2021 | |
| Alcon Vision LLC | $285.85 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Shire North American Group INC | $277.01 | 2019 | |
| Aerie Pharmaceuticals, INC. | $178.59 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $172.52 | 2022-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $155.31 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $135.56 | 2022 | |
| Abbvie INC. | $120.95 | 2022-2025 | |
| Optos, INC. | $112.34 | 2019-2022 | |
| Amgen INC. | $109.65 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $93.88 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $93.30 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $77.81 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Coopervision INC. | $77.62 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $42.22 | 2023 | |
| Maculogix, INC. | $39.41 | 2019 | |
| Eyevance Pharmaceuticals LLC | $35.48 | 2019-2022 | |
| Dompe US, INC. | $28.66 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Omeros Corporation | $18.90 | 2020 | |
| Thea Pharma INC. | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.